DexCom initiated with an In Line at Evercore ISI

Evercore ISI initiated coverage of DexCom (DXCM) with an In Line rating and $68 price target Though DexCom serves the “large and vastly underpenetrated” diabetes market, the firm’s In Line rating reflects its belief that product quality and manufacturing issues and competitive threats will continue to disrupt the company’s share gain opportunity through 2026, the analyst tells investors.